^
    2d
    Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=128, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • paclitaxel • docetaxel • fluorouracil topical
    3d
    Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, Roswell Park Cancer Institute | Trial completion date: Mar 2026 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • oxaliplatin • leucovorin calcium • fluorouracil topical
    10d
    Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov)
    P3, N=129, Not yet recruiting, City of Hope Medical Center
    New P3 trial
    |
    Avastin (bevacizumab) • irinotecan • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Jelmyto (mitomycin urothelial gel) • fluorouracil topical
    24d
    A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers (clinicaltrials.gov)
    P1, N=25, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    carboplatin • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    1m
    NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Oct 2025 --> Jan 2027 | Trial primary completion date: Apr 2025 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    1m
    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (clinicaltrials.gov)
    P1, N=49, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2026 --> Jan 2028 | Trial primary completion date: Aug 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    cisplatin • paclitaxel • doxorubicin hydrochloride • albumin-bound paclitaxel • oxaliplatin • irinotecan • daunorubicin • leucovorin calcium • Jelmyto (mitomycin urothelial gel) • fluorouracil topical
    1m
    NCI-2022-09458: FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    POLE (DNA Polymerase Epsilon)
    |
    POLE mutation
    |
    Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical
    1m
    Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer (clinicaltrials.gov)
    P1, N=25, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Signatera™
    |
    capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    1m
    2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers (clinicaltrials.gov)
    P2, N=60, Recruiting, Emory University | Trial primary completion date: Sep 2025 --> Aug 2026
    Trial primary completion date
    |
    oxaliplatin • leucovorin calcium • fluorouracil topical
    2ms
    NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical • Hensify (crystalline hafnium oxide)
    2ms
    A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses (clinicaltrials.gov)
    P3, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: May 2026 --> Oct 2025
    Enrollment open • Trial initiation date
    |
    fluorouracil topical
    2ms
    Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=35, Not yet recruiting, Roswell Park Cancer Institute
    New P1/2 trial
    |
    oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical